Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

Infectious agent detection by nucleic acid (DNA or RNA) for Neisseria gonorrhoeae, quantified under CPT® Code 87592, refers to a laboratory procedure aimed at identifying and measuring the presence of the bacterium Neisseria gonorrhoeae, which is responsible for the sexually transmitted infection known as gonorrhea. This infection can affect various parts of the body, including the reproductive tract, mouth, throat, eyes, and anus, and is primarily transmitted through direct sexual contact. While many women may remain asymptomatic, the infection can lead to serious complications, such as irreversible damage to the reproductive system, potentially resulting in infertility. In contrast, men typically exhibit symptoms such as burning sensations, itching, and discharge from the urethra, although they are less likely to experience long-term reproductive damage. The procedure involves the use of nucleic acid tests, which may include rapid testing methods that can be conducted in a physician's office using specific test kits. Specimens are collected via swabs from various anatomical sites, including the cervix, male urethra, mouth, throat, or eyes. The quantification process in CPT® Code 87592 is crucial as it not only confirms the presence of N. gonorrhoeae but also assesses the severity of the infection and the patient's response to treatment, providing valuable information for clinical decision-making.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

Testing for Neisseria gonorrhoeae is indicated in the following situations:

  • Sexually Transmitted Infection Screening Routine screening for sexually active individuals, particularly those at higher risk for gonorrhea.
  • Symptomatic Patients Evaluation of patients presenting with symptoms consistent with gonorrhea, such as urethral discharge, dysuria, or pelvic pain.
  • Asymptomatic Carriers Identification of asymptomatic carriers, especially in women, to prevent complications such as pelvic inflammatory disease (PID) and infertility.
  • Follow-Up Testing Monitoring and quantifying the infection in patients undergoing treatment to assess the effectiveness of therapy.

2. Procedure

The procedure for detecting and quantifying Neisseria gonorrhoeae involves several key steps:

  • Specimen Collection A specimen is obtained using a swab from the appropriate anatomical site, which may include the cervix in females, the male urethra, or other sites such as the throat or eyes, depending on the clinical presentation.
  • Nucleic Acid Extraction The collected specimen undergoes a process to extract nucleic acids, which involves lysing the cells to release the DNA or RNA of the N. gonorrhoeae organism.
  • Amplification of Nucleic Acids An amplification technique, such as polymerase chain reaction (PCR) or transcription-mediated amplification (TMA), is employed to create multiple copies of the nucleic acids. This step is crucial when the initial sample may contain low levels of the organism.
  • Quantification The amplified nucleic acids are then quantified to determine the concentration of N. gonorrhoeae present in the specimen. This quantification provides insights into the severity of the infection and helps in evaluating the patient's response to treatment.

3. Post-Procedure

After the procedure, the results of the nucleic acid detection and quantification will be analyzed and reported. Clinicians will use this information to guide treatment decisions and follow-up care. Patients may be advised on the importance of notifying sexual partners and may require additional testing or treatment based on the results. It is essential to monitor the patient's response to treatment, especially in cases of high quantification, to ensure effective management of the infection and to prevent complications.

Short Descr N.GONORRHOEAE DNA QUANT
Medium Descr IADNA NEISSERIA GONORRHOEAE QUANTIFICATION
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
KX Requirements specified in the medical policy have been met
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
XU Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"